GlassScriptPhysician profile
Kashif A Memon
NPI 1932161668
$72,577.57
in general payments reported to CMS, 2019-2025
26 companies · $6,285 in 2025
The $6,285 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $5,771 · 2021: $10K · 2022: $14K · 2023: $9,758 · 2024: $7,103 · 2025: $6,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $1,600 · Food and Beverage: $1,244 · Travel and Lodging: $894 · Education: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,827.50 |
| Consulting Fee | $1,600.00 |
| Food and Beverage | $1,244.36 |
| Travel and Lodging | $894.26 |
| Education | $580.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $40,941.83 | 2021-2025 | |
| Allergan, INC. | $17,776.97 | 2019-2020 | |
| Mylan Specialty L.P. | $6,353.66 | 2019 | |
| La Jolla Pharmaceutical Company | $2,266.04 | 2025 | Zevtera |
| Ferring Pharmaceuticals INC. | $1,724.95 | 2023 | Rebyota |
| Becton, Dickinson and Company | $900.00 | 2021-2023 | |
| Vertex Pharmaceuticals Incorporated | $500.00 | 2023 | |
| Melinta Therapeutics, LLC | $409.27 | 2024-2025 | Rezzayo, Kimyrsa |
| Biofire Diagnostics, LLC | $325.00 | 2020 | |
| Viiv Healthcare Company | $300.34 | 2024-2025 | Dovato |
| Cepheid | $300.00 | 2025 | |
| Zoll Medical Corporation | $203.33 | 2019 | |
| Glaxosmithkline, LLC. | $120.00 | 2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Insmed, INC. | $80.88 | 2024-2025 | Arikayce |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $47.11 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $36.90 | 2025 | Nuzyra, Xhance |
| Biomerieux INC | $35.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.18 | 2021-2022 | |
| Amgen INC. | $24.59 | 2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $21.07 | 2019 | |
| Lilly USA, LLC | $18.00 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $16.49 | 2019 | |
| Dexcom, INC. | $15.87 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $15.20 | 2025 | Wegovy |
| Verity Pharmaceuticals INC. | $13.89 | 2025 | Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashif Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.